Fecal Calprotectin Test Market by Product Type (Test Kits, Instruments), by Technology (Enzyme-Linked Immunosorbent Assay (ELISA), Lateral Flow Assay (LFA), Immunoassays), by Application (Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis), by End-Use Industry (Hospitals, Diagnostic Laboratories); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Fecal Calprotectin Test Market was valued at USD 1.4 Billion in 2023 and will surpass USD 2.7 Billion by 2030; growing at a CAGR of 10.2% during 2024 - 2030.

The fecal calprotectin test market has gained significant attention due to the increasing prevalence of inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis, as well as the growing awareness of gastrointestinal health. Fecal calprotectin serves as a biomarker for detecting intestinal inflammation, making it a crucial diagnostic tool for both identifying and monitoring IBD. With its non-invasive nature and accuracy, this test has become a vital part of clinical practice, driving market growth across multiple segments including product type, technology, application, and end-use industries.

Test Kits Are Largest Product Type Owing to Demand for Home and Point-of-Care Testing

Test kits dominate the fecal calprotectin test market as the largest product type, primarily due to their convenience and accessibility. These kits enable both home testing and point-of-care diagnostics, offering significant advantages over traditional laboratory tests. As more patients and healthcare providers opt for non-invasive, quick diagnostic tools, the demand for test kits continues to rise. The ability to perform these tests at home or in non-clinical settings provides patients with greater control over their health, further driving the market for test kits.

Additionally, the ease of use and cost-effectiveness of fecal calprotectin test kits contribute to their growing popularity. These kits not only simplify the diagnostic process but also reduce the burden on healthcare facilities, making them an attractive option for routine monitoring. As awareness of IBD and its management continues to grow, test kits are expected to maintain their leadership position in the market, particularly in regions with increasing health literacy and demand for preventive care.

Lateral Flow Assay (LFA) Technology Is Fastest Growing Owing to Rapid Results and Ease of Use

Lateral Flow Assay (LFA) technology is the fastest-growing segment within the fecal calprotectin test market, driven by its ability to deliver quick, reliable results at the point of care. Unlike other technologies that require complex laboratory setups, LFA tests provide immediate results, making them ideal for use in emergency and clinical settings where time is critical. The simplicity of the LFA method, combined with its accuracy, makes it highly suitable for widespread use, further fueling its adoption.

LFA's growing popularity is also attributed to its cost-effectiveness and minimal training requirements. This technology enables healthcare providers to make fast, informed decisions regarding patient care, particularly in diagnosing inflammatory bowel diseases and other gastrointestinal conditions. With the increasing preference for rapid diagnostic methods, LFA technology is set to play a pivotal role in the fecal calprotectin test market.

Inflammatory Bowel Disease (IBD) Is Largest Application Due to Rising Prevalence

Inflammatory Bowel Disease (IBD), which encompasses conditions like Crohn’s disease and ulcerative colitis, is the largest application segment for fecal calprotectin tests. The increasing prevalence of IBD worldwide, along with the chronic nature of these diseases, has led to a rising demand for effective diagnostic tools. Fecal calprotectin testing is a key diagnostic biomarker for detecting and monitoring inflammation in the gastrointestinal tract, making it an essential tool in the management of IBD patients.

The ability of fecal calprotectin tests to distinguish between IBD-related inflammation and other gastrointestinal conditions has further strengthened their use in clinical practice. IBD’s complex and often relapsing nature necessitates continuous monitoring, creating a sustained demand for fecal calprotectin tests. As the global burden of IBD increases, this application segment is expected to maintain a dominant position in the fecal calprotectin test market.

Hospitals Are Largest End-Use Industry Due to Advanced Diagnostics and Treatment Facilities

Hospitals are the largest end-use industry in the fecal calprotectin test market, owing to their advanced diagnostic capabilities and comprehensive treatment infrastructure. Hospitals play a critical role in the management of IBD, where fecal calprotectin tests are frequently used to diagnose, monitor disease activity, and guide treatment decisions. The centralized nature of hospital care ensures that patients have access to a wide range of diagnostic tools, including fecal calprotectin tests, for accurate and timely assessment.

Hospitals also offer specialized care for IBD patients, including advanced imaging techniques, medications, and multidisciplinary approaches. The growing prevalence of gastrointestinal disorders and the importance of early diagnosis contribute to hospitals’ central role in the fecal calprotectin test market. As healthcare systems continue to expand and evolve, hospitals will remain the dominant end-use industry for fecal calprotectin testing.

North America Is Largest Region Due to High Incidence of IBD and Advanced Healthcare Infrastructure

North America is the largest region in the fecal calprotectin test market, driven by the high incidence of inflammatory bowel diseases (IBD) and the presence of advanced healthcare infrastructure. The United States, in particular, has a high prevalence of conditions like Crohn’s disease and ulcerative colitis, which fuels the demand for effective diagnostic tools such as fecal calprotectin tests. The region benefits from well-established healthcare systems, cutting-edge research, and a growing emphasis on preventive care, all of which contribute to the widespread use of fecal calprotectin testing.

In addition, North American healthcare providers and patients are increasingly adopting non-invasive testing methods like fecal calprotectin due to their accuracy and convenience. As the region continues to invest in healthcare advancements, the demand for fecal calprotectin tests is expected to grow, further consolidating North America’s dominant position in the global market.

Competitive Landscape and Leading Companies

The fecal calprotectin test market is competitive, with a number of key players involved in the development and commercialization of innovative testing products. Leading companies such as Thermo Fisher Scientific, Abbott Laboratories, and Buhlmann Laboratories are at the forefront of the market, offering a range of fecal calprotectin test kits and instruments. These companies are focusing on enhancing the accuracy, ease of use, and affordability of their products to cater to a growing global demand.

In addition to established players, numerous startups and emerging companies are entering the market with new, advanced diagnostic technologies aimed at improving the detection and monitoring of inflammatory bowel diseases. Companies are also investing in strategic partnerships, product innovations, and research collaborations to maintain a competitive edge in this rapidly evolving market. As the demand for non-invasive, rapid, and reliable diagnostics continues to rise, these companies will remain central to shaping the future of the fecal calprotectin test market.

List of Leading Companies:

• Abbott Laboratories
• Becton, Dickinson and Company (BD)
• bioMérieux S.A.
• Cepheid (Danaher Corporation)
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Labor Diagnostika Nord GmbH
• Medtronic PLC
• Omega Diagnostics Group PLC
• Orion Diagnostica Oy
• Quidel Corporation
• Roche Diagnostics
• Siemens Healthineers
• Thermo Fisher Scientific Inc.

Recent Developments:

• Thermo Fisher Scientific introduced an advanced fecal calprotectin test with improved sensitivity and faster results for IBD diagnosis.
• Abbott Laboratories launched a new fecal calprotectin assay that provides accurate results within minutes, reducing wait times for patients.
• Roche Diagnostics expanded its fecal calprotectin test portfolio, aiming to enhance IBD management by enabling more frequent monitoring.
• Medtronic PLC entered into a partnership to develop a point-of-care fecal calprotectin testing device for early diagnosis of gastrointestinal diseases.
• Siemens Healthineers received regulatory approval for its new fecal calprotectin test kit, designed to enhance the accuracy of IBD diagnosis

Report Scope: